Printer Friendly
The Free Library
14,715,918 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Kissei Pharmaceutical to License KGA, Diabetes Drug Candidate, to GlaxoSmithKline.


Tokyo, Japan, Apr 8, 2006 - (JCN JCN Japan Corporate News
JCN Journal of Cognitive Neuroscience
JCN Journal of Cardiovascular Nursing
JCN Journal of Christian Nursing
JCN Job Control Number
JCN Journal of Child Neurology
JCN joint communications network (US DoD) 
) - Kissei Pharmaceutical announced on April 6 that it has concluded a licensing agreement with GlaxoSmithKline (GSK) for KGA, Kissei Pharmaceutical's proprietary candidate compound for diabetes drug.

Under the agreement terms, GSK will be able to exclusively develop and market the agent worldwide except in Japan, Korea, China and Taiwan, in exchange for making an upfront payment, milestone payments on product development, and royalties on future sales to Kissei Pharmaceutical.

KGA is a selective inhibitor for SGLT SGLT Sodium-Glucose Linked Transporter
SGLT Space-Ground Link Terminal
1 (sodium-dependent glucose transport 1) which inhibits intestinal sugar absorption and improves postprandial postprandial /post·pran·di·al/ (-pran´de-al) occurring after a meal.

post·pran·di·al
adj.
Following a meal, especially dinner.
 hyperglycemia hyperglycemia: see diabetes. . Currently, Kissei Pharmaceutical undertakes nonclinical studies of the agent. Going forward, GSK will proceed with clinical studies abroad.

Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2006 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Date:Apr 8, 2006
Words:123
Previous Article:NTT Data to Promote Generic Drug Prescription.
Next Article:Asahi Glass to Expand Its Recombinant Protein Manufacturing Facility.



Related Articles
454 LIFE SCIENCES GETS GENOME LICENSE FROM PYROSEQUENCING.
MediciNova, Inc. Acquires Phase II Premature Labor Compound from Kissei Pharmaceutical Co., Ltd.; Vice President, Regulatory Affairs Appointed to...
OSI INITIATES PHASE I CLINICAL TRIAL OF PSN357.
BIOVITRIM/SANTHERA SIGN PACT FOR DEVELOPING DPP-IV.
Kissei Pharmaceutical, JCR Pharmaceuticals Enter into Joint Research Agreement for JR-013, Recombinant Human Erythropoietin-based Renal Anemia Agent.
Kissei Pharmaceutical Obtains Manufacturing Approval for URIEF Capsule, Benign Prosatic Hypertrophy Drug.
Elixir Pharmaceuticals Acquires Late-Stage Product for the Treatment of Type II Diabetes.
Kissei Pharmaceutical, Daiichi Pharmaceutical Jointly Launch Urination Disorder Improving Drug.
Research and Markets: Sales for the Pharmaceutical Company Takeda Increased by 7% to Reach 935,213 Million Yen.
ASTELLAS' SCREENING TRIGGERS MILESTONE PAYMENT TO METABOLEX.

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles